Walleye Capital
AMLX icon

Walleye Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Walleye Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Sell
1,800
-7,100
-80% -$99.9K ﹤0.01% 4042
2025
Q4 		$108K Buy
8,900
+2,100
+31% +$28.5K ﹤0.01% 3841
2025
Q3 		$92.4K Buy
+6,800
New +$64K ﹤0.01% 3739
2025
Q1 		– Sell
-33,500
Closed -$127K – 4205
2024
Q4 		$127K Buy
+33,500
New +$158K ﹤0.01% 4019
2024
Q2 		– Sell
-100
Closed -$284 – 5548
2024
Q1 		$284 Buy
+100
New +$1.31K ﹤0.01% 5348
2023
Q4 		– Sell
-1,800
Closed -$33K – 4901
2023
Q3 		$33K Buy
+1,800
New +$38.1K ﹤0.01% 4295
2023
Q1 		– Sell
-6,700
Closed -$248K – 3898
2022
Q4 		$248K Buy
+6,700
New +$238K ﹤0.01% 1908

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Walleye Capital's AMLX Position: Q1 2026 in Review

Walleye Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 975% in Q1 2026, buying an estimated $787K and bringing the position to 61,711 shares worth $858K. The position accounts for ﹤0.01% of the portfolio, ranked #2218.

Walleye Capital first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $8.58M in Q4 2023. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Walleye Capital held 61,711 shares of Amylyx Pharmaceuticals worth $858K as of Q1 2026.
  • Walleye Capital bought 55,971 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $787K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2218 holding.
  • Walleye Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Walleye Capital's Amylyx Pharmaceuticals position peaked at $8.58M in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.